Volume 35, Issue 32, Pages 3905-4056 (13 July 2017)
The $100,000 vaccine challenge: Another method of promoting anti-vaccination pseudoscience
Craig A. Foster
Vaccination resilience: Building and sustaining confidence in and demand for vaccination
Eve Dubé, Noni E. MacDonald
ADE and dengue vaccination
Ruth Aralí Martínez-Vega, Gabriel Carrasquila, Expedito Luna, José Ramos-Castañeda
The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers. In this work, we intend to contribute to the debate by analyzing the concept of an enhancing vaccine, presenting objections to the epidemiological model base of the concept and, likewise, presenting data that contradict that concept.